openPR Logo
Press release

Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz

10-26-2017 01:01 PM CET | Health & Medicine

Press release from: ISA Pharmaceuticals

/ PR Agency: akampion
- Ceremony Conventio Medicinae held at University Medical Center

Leiden, The Netherlands, October 26, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that its Chief Scientific Officer, Prof. Cornelis Melief, has received an honorary doctorate from the University Medical Center of Johannes Gutenberg University Mainz, Germany. The honorary doctorate was awarded during a festive ceremony in Mainz on October 25, 2017.

Prof. Melief was recognized for his lifetime achievements as a pioneer in tumor immunology and his special merits regarding immunological research in Mainz.

"It is a special honor for me to award Prof. Cornelis Melief with the honorary doctorate of University Medical Center Mainz," said Prof. Dr. Ulrich Foerstermann, Scientific Director and Dean, University Medical Center Mainz. "We recognize him as the doyen of European tumor immunology as he is regarded as a pioneer in immunotherapeutic treatment strategies against cancer. Moreover, this honorary doctorate also expresses our close relationship with Professor Melief, who for many years has been an esteemed and committed advisor and mentor of various programs at our immunotherapy research center."


About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In addition, ISA develops MyISA®, a personalized SLP® immunotherapy, targeting tumor-specific, mutation-derived neo-antigens.
For more information, please visit

SLP®, AMPLIVANT® and MyISA® are registered trademarks in Europe.

Contact & Media Inquiries:
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, Tel. +49 30 23 63 27 68

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz here

News-ID: 787132 • Views: 215

More Releases from ISA Pharmaceuticals

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019. The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute. The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC) Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810). This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019. The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00

All 5 Releases

More Releases for University

Nursing Education Market Can Become Bigger in Five Years? Key Players Duke Unive …
The Nursing Education Market Research Report aims to provide insights that strongly demonstrate the market structure, scope, history, potential, and development perspective. By crossing through the historical and present market status, the Nursing Education market report provides authentic and reliable estimates for the forecast period. The report presents the market competitive landscape and consistent in-depth analysis of the major vendor/key players in the market along with the impact of economic
Nursing Education Market Research Report 2020-2027| Duke University, Johns Hopki …
An informative data report titled Nursing Education Market was published by The Research Insights. It takes a closer look at the different aspects of the businesses, that are responsible for fueling the growth of the companies. Additionally, it offers some significant factors, which are restraining the progress of the industries. Primary and secondary research techniques have been used by analysts to study the data effectively. The global market is estimated
KLE Technological University partners with Coventry University, UK
KLE Tech, in its endeavour to create better learning environments to students and giving them multi-cultural exposure, has entered into a MoU with Coventry University (, one of the leading universities of United Kingdom. Prof.Ashok Shettar, Vice Chancellor signed the MoU with Prof.Richard Dashwood, Deputy Vice-Chancellor (Research) of Coventry University on October 08, 2018. As per this MoU, both Universities would be collaboratively working in the areas of research, faculty development
Banasthali Vidyapith – University for Women & University with a Difference
Every educational institution in India today has a name but only very few like Banasthali have a legacy. The evolution of Banasthali is nothing short of a fairy tale in which the parents freedom fighter and Gandhian Pt Hiralal Shastri and Padma Bhushan & Jamnalal Babaj Award winner Smt Ratan Shastri took up the mission with passion for setting up an institution at Banasthali to fulfill the desire of their
COPEAC Affiliate Network Launches Exclusive Education Portal Woodbury, NY (January 26, 2011) – COPEAC, IMM Interactive’s exclusive affiliate network, is one of the largest and most respected performance-based ad networks in the digital advertising sector with over 40K publishing partners. For these partners, COPEAC is offering an exclusive education tool called COPEAC University; an online education portal with valuable resources for success in Affiliate Marketing. Offered exclusively for COPEAC members, COPEAC
University of South Africa, Number One Online University in Africa
According to the 2010 edition of the Best Worst Online Degree Programs, the University of South Africa is ranked the number one online degree provider among Africa’s 53 nations. The University of South Africa’s vision is to be Africa’s premier distance learning institution. It would appear, according to the e-book that they have succeeded. The university’s roots go back over 130 years. The Division of External Studies was created